National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Elosulfase alfa (Vimzim®) is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome, MPS IVA) in patients of all ages.

Rapid Review

Commenced Completed Outcome
30/03/2015 08/05/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
04/04/2016  08/12/2016 Reimbursement Not Recommended

The cost effectiveness of elosulfase alfa (Vimizim®) has not been demonstrated. Therefore it is not recommended for reimbursement


The HSE has approved reimbursement following confidential price negotiations: May 2018